# Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury

> **NCT06548802** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tianjin Medical University General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Pulmonary Injury After Intracerebral Hemorrhage

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT06548802
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06548802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06548802, "Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06548802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*